Summary Glucose metabolism was evaluated in transgenic mice expressing the human GLUT 4 glucose transporter. Fed GLUT 4 transgenic mice exhibited a 32 % and 56 % reduction in serum glucose and insulin and a 69 % and 33 % increase in non-esterified fatty acid and lactate levels, respectively. Transgenic mice exhibited a significant increase in whole-body glucose disposal during a euglycaemic-hyperinsulinaemic clamp. Insulin-stin'mlated glucose uptake in isolated soleus muscles and adipocytes was greater in transgenic compared to control mice due to increased basal glucose uptake. Transgenic mice displayed increased glycogen levels in liver and gastrocnemius muscle, and increased insulin-stimulated 14C-glycogen accumulation in isolated soleus muscle. We conclude that over-expression of the GLUT 4 glucose transporter in mice results in 1) an increase in whole-body glucose disposal and storage, and 2) an increase in both basal and insulin-stimulated glucose uptake and disposal in vitro. These changes resulted in the reduction of serum glucose and insulin levels. These results provide direct evidence that glucose transport (and GLUT 4 per se) plays a significant role in regulating wholebody glucose homeostasis. Additionally, these data support the idea that pharmacological strategies directed at increasing the expression of GLUT 4 protein may have beneficial (hypoglycaemic) effects in the diabetic state. [Diabetologia (1994[Diabetologia ( ) 37: 1097[Diabetologia ( -1104 
glucose transport proteins [8, 9] . GLUT 1 is present in skeletal muscle and fat and is primarily responsible for constitutive (basal) glucose uptake. GLUT 4 is the most abundant transporter isoform in these insulin-sensitive tissues, and is responsible for the vast majority of insulin-stimulated glucose transport [10] [11] [12] . Under basal conditions, GLUT 4 is present in a pool of vesicles localized to intracellular membranes. Following insulin stimulation or exercise, these vesicles are rapidly recruited to the plasma membrane [13] [14] [15] [16] , along with additional vesicle-associated proteins that may be involved in the regulation of vesicular trafficking [17] [18] [19] . In adipocytes and muscle, the redistribution of GLUT 4 can quantitatively account for the increase in insulin-stimulated glucose transport [20] [21] [22] .
Considerable research has been directed toward determining whether the expression of GLUT 4 is altered in obesity or NIDDM or both. What has be-come clear from studies evaluating rodent models of diabetes, and from human studies, is that GLUT 4 expression is subject to tissue-specific regulation. In streptozotocin-treated rats, the amount of GLUT 4 in skeletal muscle is unaltered, but is reduced by more than 90 % in adipocytes [23, 24] . In Zucker diabetic rats, which are insulin resistant, hyperinsulinaemic, and obese, GLUT 4 is also significantly reduced in adipocytes [25] . Most studies, but not all [25] , report that GLUT 4 is unchanged in skeletal muscle [26] [27] [28] [29] . This may be related to the extent of the diabetic state. Similarly, in obese humans and those with NIDDM, the level of GLUT 4 protein is markedly reduced in adipocytes [3, 4] , but not in skeletal muscle [30] [31] [32] . Thus, data from rodent models and humans point to a mechanism other than an absolute reduction in GLUT 4 as the principal reason for impaired insulin-stimulated glucose transport in skeletal muscle, although it could be sufficient to account for the impairment in adipose tissue.
Whether or not a reduction in GLUT 4 expression is a significant factor leading to or resulting from insulin resistance associated with obesity or NIDDM, the central role of this facilitative transporter in mediating insulin-stimulated glucose transport suggests that it might be important in regulating whole-body glucose homeostasis [33] . Thus, it is intriguing to consider a novel therapeutic strategy for those disorders that emphasize the selective positive regulation of GLUT 4 protein levels. In an attempt to evaluate the physiological consequences of this approach, our group has recently reported the development of transgenic mice that express the human GLUT 4 glucose transporter gene under the control of its own promoter [34] . This transgene is expressed tissue specifically with the quantitatively greatest expression (mRNA and protein) in heart, skeletal muscle, and adipose tissue, respectively. Expression of the human GLUT 4 protein results in a significant reduction in serum glucose and insulin levels, and an increase in lactate [34] . The purpose of the present study was to further examine the impact on carbohydrate and lipid metabolism of human GLUT 4 expression in mice. Specifically, whole-body glucose disposal was assessed by employing the euglycaemic-hyperinsulinaemic clamp. Additionally, basal and insulin-stimulated glucose uptake were assessed in isolated soleus muscle and adipocytes. Finally, glycogen metabolism was assessed by measuring 14C-glycogen accumulation from 14C-glucose in isolated muscle, along with the determination of tissue glycogen levels.
Materials and methods
Animals. The production of mice expressing the human GLUT 4 gene has been described previously [34] . Adult male and female hemizygous mice from a single GLUT 4 transgenic foun-R.O. Deems et al.: GLUT 4 transgenic mice der (approximately 14 copies of the human GLUT 4 gene) were used in all studies described here. Animals were housed under standard laboratory conditions with a 12:12 h light:dark cycle and were fed Purina rodent chow ad libitum, except when fasted overnight.
Western blot analysis. Tissues were homogenized at 0-4 ~ in a buffer containing 20 mmol/1 HEPES (pH 7.4), 0.25 mol/1 sucrose, 3 mmol/1 dithiothreitol, 1 mmol/1 EDTA, 0.1 mmol/1 PMSF and leupeptin, aprotinin and pepstatin A, each at 100 ~tg/ml. Cell homogenates were layered on a 1.2 mmol/1 sucrose cushion and centrifuged at 100,000 x g for 1 h. Total membranes above the interface were collected and sedimented by centrifugation at 200,000 x g for I h at 4 ~ and resuspended in homogenization buffer. The protein concentration of each sample was determined by the Coomassie Brilliant Blue method (Pierce, Rockford, Ill., USA) with bovine albumin as standard. Equal amounts of total membrane protein were subjected to 10 % SDS-polyacrylamide gel etectrophoresis and electrophoretically transferred to nitrocellulose filters. Membranes were blocked for 2 h with 4 % Carnation low-fat instant milk in Tris-buffered saline (TBS) containing 0.02 % Tween, followed by incubation at room temperature for 16 h with the 1F8 monoclonal antibody (East Acres Biologicals, Southbridge, Mass., USA), specific for the GLUT 4 glucose transporter protein [35] . Blots were then washed for 10 min five times in TBS and incubated for 3 h in TBSTween-dry milk with I25I-labelled protein A (Amersham Corp., Arlington Heights, Ill., USA) with horseradish peroxidase-conjugated goat anti-mouse IgG. After five further washes, immunospecific bands were detected. Bands were evaluated by exposure to phosphor screens followed by visualization and quantitation using a PhosphorImager with ImageQuant software (Molecular Dynamics, Sunnyvale, Calif., USA).
Metabolic analyses. Serum was obtained via cardiac puncture from fed normal and transgenic female mice anaesthetized with CO2. Glucose and lactate levels were analysed with glucose oxidase and lactate oxidase, respectively, using an automated analyzer (Yellow Springs Instruments, YSI 27 or 2700, Yellow Springs, Ohio, USA). Non-esterified fatty acid (NEFA) levels were measured using the acyl-CoA synthetase and acyl-CoA oxidase method (Wako Pure Chemical Industries, Richmond, Va., USA). Insulin was measured in whole serum by radioimmunoassay employing a guinea-pig anti-rat insulin antibody, 125I-porcine insulin, rat insulin standards, and polyethylene glycol-accelerated 2nd antibody precipitation. The sensitivity of this assay is approximately 0.1 ~tU/ml, and the inter-and intra-assay coefficients of variation are typically 7.0 % and 8.0 %, respectively.
Euglycaemic-hyperinsulinaemic clamp. Cannulas were surgically implanted [36] into the jugular vein and carotid artery of overnight (18 h) fasted female mice anaesthetized with sodium pentobarbital (50 mg/kg). Animals remained anaesthetized for the duration of the study. Anaesthesia during the clamp was maintained by a low dose of isofluorane (0.2-0.5 % volume). Insulin and glucose were infused into the jugular vein; the carotid artery was used for blood sampling. Insulin (3 mUkg-lmin -1) was infused at a rate of 10 ~tl/min, after a priming dose of 20 ~tl/min for the first 10 min. Blood glucose levels were determined at 5-min intervals for 120 min. A variable rate of glucose (dextrose, 2 % w/v) was infused to maintain blood glucose levels at approximately 5-5.6 mmol/l. At the conclusion of the experiment, animals were killed with an overdose of anaesthesia.
2-Deoxyglucose uptake in isolated muscle. 2-Deoxyglucose up-
take was assayed in isolated muscle as described previously [37] . Briefly, soleus muscles from 18 h fasted male mice were surgically excised and incubated for 15 min at 37 ~ in KrebsHenseleit buffer. The muscles were then incubated for 60 min in Erlenmeyer flasks in media containing 2-[3H]deoxy-D-glucose (5 mmol/1 final concentration) in the absence or presence of insulin as indicated. Following incubation, muscles were homogenized and processed for scintillation counting.
3H-glucose incorporation into lipid. Adipocytes were isolated
from the epididymal fat pads of fed control and transgenic mice by collagenase digestion [38] . There was no significant difference in cell size between normal control and transgenic mice as determined by electron microscopy of an aliquot of adipocytes corresponding to approximately 0.15 % of the total number employed for the assay (data not shown). Cells (2 % v/v final concentration corresponding to approximately 6 x 1 0 4 cells/ml) were preincubated for 30 min at 37 ~ with 1 U/ml adenosine deaminase, which was added to remove endogenous adenosine [39] , and insulin as indicated. Adenosine deaminase did not affect the fragility of the adipocytes as evidenced by the absence of free fat droplets. Following preincubation, [3-3H]-D-glucose (0.5 btCi/ml, 50 ~tmol/1 final concentrations) was added, and the incubation continued for 60 min. Incubations were terminated by the addition of 5 ml of a toluenebased scintillant to each reaction vessel. Incorporation of 3H-glucose into cellular lipid (a reliable indicator of glucose transport under these conditions) was determined by liquid scintillation counting following overnight phase-separation at 4~ Under these assay conditions, the radioactivity associated with water-soluble molecules (including unincorporated 3H-glucose) is not counted to a significant degree [40] .
Glycogen accumulation. Glycogen accumulation in isolated soleus muscle was determined as described previously [41] . Soleus muscles were isolated from 18 h fasted normal and transgenic male mice. Insulin was added to the incubation media as indicated.
Tissue glycogen. Glycogen was determined by a modification of the method of Chan and Exton [42] . Tissue samples for glycogen analysis were rapidly frozen in liquid nitrogen, and stored at -70 ~ Approximately 100 mg of each tissue was extracted with i ml of ice-cold 30 % (w/v) perchloric acid for i h at 4 ~ Following centrifugation in a microfuge, 10 bl of the supernatant was spotted on 7-mm Whatman 3MM paper disks (Hillsboro, Oregon, USA). The disks were washed three times in 66 % EtOH for 15 min. The filters were dried and placed into wells of a 96-well microtiter plate along with 100 bd acetate buffer containing 0.1 ~tg/btl amyloglucosidase (53 U/mg). The plate was incubated for 90 min at 37 ~ after which time 50 bd of the incubation mixture was assayed for glucose using glucose oxidase (Ciba-Corning/Gilford, #$1004B, Oberlin, Ohio, USA). The perchloric acid pellets remaining after centrifugation were digested overnight at room temperature with 0.8 N NaOH and for an additional 1 h at 60~ and assayed for protein content [43] . lanes 1-4) , skeletal muscle (25 g, lanes 5-8) and heart (25 g, lanes 9-12) from two control (lanes 1,2,5,6 ,9,10) and two GLUT 4 transgenic mice (lanes 3,4,7,8,11,12 ) were electrophoresed and immunoblotted with the 1F8 monoclonal antibody Results are expressed as mean _+ SEM for five to six mice per group, ap < 0.05, Up < 0.001, compared to control
Results

Western blot analysis. The level of expression of
G L U T 4 glucose t r a n s p o r t e r protein ( h u m a n plus murine) was e v a l u a t e d by W e s t e r n blotting with the a n t i -G L U T 4 m o n o c l o n a l a n t i b o d y IF8 of total m e mb r a n e proteins isolated f r o m epididymal adipose tissue, cardiac and skeletal muscle (hindlimb), liver, brain, kidney and small intestine of transgenic and control mice. A n t i b o d y IF8 binds b o t h h u m a n and m o u s e G L U T 4 proteins. G L U T 4 p r o t e i n was detected as a b r o a d b a n d of a p p r o x i m a t e l y 45-50 k D a (Fig. 1) . In c o m p a r i s o n to controls, transgenic animals had at least twofold greater expression of G L U T 4 protein in adipose tissue and three to fourfold g r e a t e r expression in skeletal and cardiac muscle. Levels of G L U T 4 p r o t e i n were substantially greater in heart than in skeletal muscle.
Metabolic analyses. S e r u m levels of glucose, lactate, insulin, and N E F A f r o m fed control and transgenic mice are p r e s e n t e d in Table 1 . G l u c o s e and insulin levels were significantly r e d u c e d by 32 % and 56 %, respectively, in transgenic animals c o m p a r e d to controls. L a c t a t e and N E F A levels were increased by 33 % and 69 %, respectively, in transgenic vs control mice.
Statistical analyses
Statistical significance was assessed by the Student's t-test or by ANOVA followed by Student's t-test for individual comparisons.
Euglycaemic-hyperinsulinaemic clamp. W h o l e -b o d y insulin action was e v a l u a t e d in five G L U T 4 transgenic mice and five control littermates. Glucose levels were c l a m p e d at a p p r o x i m a t e l y 5.5 mmol/1.
The m e a n glucose levels for the interval of 80-120 rain were c o m p a r a b l e for control and transgenic mice ( Table 2) . D u r i n g this interval the glucose infu- Table 2 ). 
2-Deoxy
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3H-glucose incorporation into lipid. Glucose uptake was also assessed in isolated adipocytes. In the absence of insulin, basal glucose uptake was 3.2 times higher in transgenic mice as compared to control littermates (Fig.3) . Tissue glycogen. In mice fed ad libitum, glycogen levels were significantly elevated in liver @4-fold), heart @2.5-fold), and gastrocnemius muscles (-2.5-fold) from transgenic mice compared to littermates (Fig.5) . No statistically significant differences between groups were observed in the glycogen levels of soleus muscles. After an overnight fast, liver glycogen was substantially depleted in both transgenic and control mice and was no longer significantly different 1101 (Fig. 5) . In contrast, fasting had no significant effect (compared to fed animals) on glycogen in gastrocnemius muscle from either group and remained significantly higher @2-fold) in transgenic vs control mice. Interestingly, fasting had no significant effect on cardiac muscle glycogen in control littermates, but produced an approximate 3-fold increase in glycogen in transgenic mice.
Discussion
Tissue-specific overexpression of the GLUT 4 glucose transporter in mice resulted in a pronounced increase in glucose utilization. The transgene was expressed in insulin-sensitive tissues of muscle, and to a lesser extent, fat. Enhanced glucose utilization was manifested by a significant increase in the wholebody glucose infusion rate during a euglycaemic hyperinsulinaemic clamp and by increased glucose uptake in both skeletal muscle and adipose tissue. The net result of these metabolic alterations was a 32 % reduction in serum glucose levels coupled with a 56 % reduction in serum insulin levels. There was also a 69 % elevation in NEFA levels which was likely a result of the reduction of insulin-inhibited lipolysis. The glucose, insulin, and lactate results confirm those previously reported [34] . The reduced level of insulin in transgenics presumably reflects a compensatory mechanism on the part of the beta-cell consequent to an increase in whole-body insulin sensitivity. Studies are currently ongoing to confirm this experimentally. Although the transgenic mice were able to dispose of part of the glucose through enhanced storage as glycogen, the elevation in serum lactate levels suggests that the capacity for this pathway was exceeded. Glycogen levels in fed mice were increased between 2-to 4-fold in liver, and cardiac and gastrocnemius muscles of transgenic mice compared to controls. This may be related to NEFA levels as Jenkins and colleagues [44] have demonstrated that high levels of NEFAs (4 mmol/1) promote glucose utilization and storage in skeletal muscle. The increase in liver glycogen levels may be a result of the elevated circulating lactate levels, which has been reported to be the primary substrate for hepatic glycogen synthesis [45] .
Surprisingly, cardiac glycogen levels in fasted transgenic mice were elevated above those observed in either fed transgenic or in fed or fasted control mice. The combination of enhanced GLUT 4 expression in cardiac muscle along with the suppression of phosphofructokinase (PFK) activity which occurs in the fasted state [45] possibly account for this observation. GLUT 4 expression in these transgenic animals is substantially higher in heart than in hindlimb muscle (C. Isaacson and R Bell, unpublished observations). This enhanced po-tential for glucose transport could drive the flux of glucose towards the production of glucose 6-phosphate. In the fed state, glycolysis would serve as the principal pathway for glucose 6-phosphate metabolism. However, in the fasted state when energy requirements are satisfied by ketone and fatty-acid oxidation, inhibition of PFK by elevated citrate levels would decrease basal glycolysis and favour glycogenesis. Plasma glucose concentration was low during fasting but due to the combination of increased glucose transport, the lack of glucose-6-phosphatase in muscle, and the inhibition of PFK, glycogenesis presumably becomes the dominant route of glucose disposal in cardiac tissue. Inhibition of hexokinase activity by high levels of glucose 6-phosphate has been reported [46] , and although glucose-6-phosphate was not measured in this study, the marked glycogen accumulation argues against a major effect of feedback inhibition.
Basal glucose uptake tended to be elevated in isolated soleus muscle and was significantly higher in adipocytes from transgenic mice. Glucose uptake in both tissues could be further stimulated by insulin resulting in a maximal uptake rate which was additive with the maximal rate observed for control littermates. These data demonstrate that the human GLUT 4 transporter protein was functional in transgenic mice resulting in the constitutive elevation of glucose transport. This observation is in agreement with an earlier study which found that overexpression of GLUT 4 under the control of the fat-specific aP2 promoter results in a dramatic enhancement of basal glucose transport [47] and suggests that overexpression may have saturated the intracellular pool of GLUT 4 resulting in plasma membrane targeting. Although the data indicate that this transporter was responsive to insulin, they do not provide evidence as to its cellular localization. Studies are currently in progress to assess this issue, and to determine if recruitment to the plasma membrane occurs following insulin stimulation.
Alterations in muscle GLUT 4 levels in diabetes and obesity tend to be modest relative to changes in adipose tissue. Some animal models of diabetes and obesity, such as the Zucker Diabetic Fatty (ZDF) or streptozotocin-induced diabetic rats show reduced GLUT 4 levels in muscle [48, 49] , while others show no changes compared to controls [50] . In NIDDM patients, Pedersen and colleagues [30] found no changes in GLUT 4 mRNA or protein levels compared to lean or obese controls. As noted by Klip and associates some of the differences may be accounted for by translocation [51] . Measurement of total number of glucose transporters may not reflect actual recruitment to the membrane. It is also clear that factors such as muscle fiber type [49] and diet [26] may influence GLUT 4 expression and thus further complicate comparisons between studies.
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Recently, several laboratories have begun to characterize lines of transgenic mice overexpressing either GLUT 1 or GLUT 4 glucose transporters [47, [52] [53] [54] . As in the present study, GLUT 1 transgenic mice also showed reduced glucose levels, but alternatively insulin levels were normal [52] . Furthermore, basal 2-deoxyglucose uptake in isolated muscles was substantially increased compared to controls [52] . These results would be predicted since GLUT 1 is considered to be the basal glucose transporter. Further, considering that GLUT 4 is the insulin-responsive glucose transporter, it is perhaps not surprising that GLUT 4 transgenic mice would show elevations in insulin-stimulated but not in basal glucose transport in muscle. Alternatively, the present results also demonstrated that both basal and insulin-stimulated glucose transport were elevated in adipose tissue. This was also observed in a recent report of transgenic mice overexpressing GLUT 4 selectively in fat [47] . In these mice, fasting glucose levels were decreased (-20 %) and insulin levels were unchanged in the fasted state but were decreased (-40 % in the fed state; [47] ).
In summary, carbohydrate metabolism has been described in a unique animal model of GLUT 4 overexpression. The results indicate that overexpression of the GLUT 4 glucose transporter in mice produced a pronounced increase in glucose utilization with an overall reduction in glucose and insulin levels. Thus, the data indicate that modest enhancements in GLUT 4 levels could serve as an approach for potential treatment for insulin resistance of diabetes.
